| Item Type | Name |
|
Concept
|
Adverse Drug Reaction Reporting Systems
|
|
Concept
|
Immunotherapy
|
|
Concept
|
Immunoassay
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Immunoenzyme Techniques
|
|
Concept
|
Receptors, TNF-Related Apoptosis-Inducing Ligand
|
|
Concept
|
Relative Biological Effectiveness
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
TNF-Related Apoptosis-Inducing Ligand
|
|
Academic Article
|
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
|
|
Academic Article
|
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation.
|
|
Academic Article
|
Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
|
|
Academic Article
|
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.
|
|
Academic Article
|
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
|
|
Academic Article
|
MK 886 functions as a radiomimetic agent: genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells.
|
|
Academic Article
|
Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.
|
|
Academic Article
|
Other compounds and targets in non-small cell lung cancer.
|
|
Academic Article
|
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
|
|
Academic Article
|
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
|
|
Academic Article
|
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
|
|
Academic Article
|
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.
|
|
Academic Article
|
Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
|
|
Academic Article
|
Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
|
|
Academic Article
|
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
|
|
Academic Article
|
Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum.
|
|
Academic Article
|
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
|
|
Academic Article
|
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
|
|
Academic Article
|
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
|
|
Academic Article
|
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
|
|
Academic Article
|
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
|
|
Academic Article
|
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
|
|
Academic Article
|
Associations between sinus tachycardia and adverse cardiovascular outcomes and mortality in cancer patients.
|
|
Concept
|
Antineoplastic Agents, Immunological
|